Prevalence and persistence of human papillomavirus in postmenopausal age women

Cancer Detection and Prevention

Volumn 27, Issue 6, 2003, Pages 472-480

  Smith, Elaine M ^a   Ritchie, Justine M ^a   Levy, Barcey T ^b   Zhang, Wei ^a   Wang, Donghong ^a   Haugen, Thomas H ^b,c   Turek, Lubomir P ^b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Hormone replacement therapy; HPV; Persistence; Postmenopausal; Prevalence

Indexed keywords

EID: 0345598879     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(03)00104-1     Document Type: Conference Paper

References (41)

1. Madeleine MM, Daling JR, Carter JJ, et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst 1997;89:1516-23.
2. Hildesheim A, Han C-L, Brinton LA, Kurman RJ, Schiller JT. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiology case-control study. Obstet Gynecol 1997;90:748-54.
3. Daling JR, Sherman KJ, Hislop TG, Maden C, Mandelson MT, Beckmann AM, Weiss NS. Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol 1992;135:180-9.
4. Liaw K, Glass A, Manos M, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical and squamous intraepithelial lesions. J Natl Cancer Inst 1999;91:954-60.
5. Mandelblatt J, Richart R, Thomas L, et al. Is human papillomavirus associated with cervical neoplasia in the elderly? Gynecol Oncol 1992;46:6-12.
6. Negrini BP, Schiffman MH, Kurman RJ, et al. Oral contraceptive use, human papillomavirus infection, and risk of early cytological abnormalities of the cervix. Cancer Res 1990;50:4670-5.
7. Brinton LA. Oral contraceptives and cervical neoplasia. Contraception 1991;43:581-95.
8. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). J Am Med Assoc 2002;288:58-66.
9. Newcomb PA, Egan KM, Trenthan-Dietz A. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:593-600.
10. Lacey Jr JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. J Am Med Assoc 2002;288:334-41.
11. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321-33.
12. Smith EM, Johnson SR, Figuerres EJ, Mendoza M, Fedderson D, Haugen TH, Turek LP. The frequency of human papillomavirus detection in postmenopausal women on hormone replacement therapy. Gynecol Oncol 1997;65:441-6.
13. Munoz N, Kato I, Bosch FX, et al. Risk factors for HPV DNA detection in middle-aged women. JSTD 1996;23:504-10.
14. Ferenczy A, Gelfand M, Franco E, Mansour N. Human papillomavirus infection in postmenopausal women with and without hormone therapy. Obstet Gynecol 1997;90:7-11.
15. McEvoy GK, Litvak K, Welsh OH, editors. American hospital formulary service 97. Drug information guide. Bethesda, MD: American Society for Health System Pharmacies; 1997.
16. Summersgill KS, Smith EM, Kirchner HL, Haugen TH, Turek LP. p53 polymorphism, human papillomavirus infection, and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:334-9.
17. Altschul SF, Madden TL, Schaeffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997;25:3389-402.
18. Bauer H, Bauer HM, Ting Y, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. J Am Med Assoc 1991;265:472-7.
19. Maniatis T, Fritsch E, Sambrook J. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
20. Chehab FF, Doherty M, Cai SP, Kan YW, Cooper S, Rubin EM. Detection of sickle cell anaemia and thalassaemias [letter]. Nature 1987;329:293-4 [published erratum appears in Nature 1987; 329(6141):678].
21. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
22. de Roda Husman A-M, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995;76: 1057-62.
23. Soong RB, Iacopetta J. A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors. Mod Pathol 1997;10:252-8.
24. Rosner B. Fundamentals of biostatistics. 5th ed. Pacific Grove, CA: Duxbury Publishers; 2000.
25. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 1989.
26. SAS system for Windows. Version 8.0. Cary, NC: SAS Institute; 1999.
27. SEER Stat3.0. Silver Springs, MD: NCI Information Management Services Inc.; 2000.
28. Brown MR, Noffsinger A, First MR, Penn I, Husseinadeh N. HPV subtype analysis in lower genital neoplasms of female renal transplant recipients. Gynecol Oncol 2000;79:220-4.
29. Sturgeon SR, Brinton LA, Devesa SS, Kurman RJ. In situ and invasive bulbar cancer incidence trends. Am J Obstet Gynecol 1992; 166:1482-5.
30. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
31. Wallin K-L, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-8.
32. Brisson J, Bairati I, Morin C, et al. Determinants of persistent detection of human papillomavirus DNA in the uterine cervix. J Infect Dis 1996;173:794-9.
33. Hildesheim A, Reeves WC, Brinton LA, et al. Association of oral contraceptive use and human papillomavirus in invasive cervical cancers. Int J Cancer 1990;45:860-4.
34. Hopman EH, Rozendaal L, Voorhorst FJ, Walboomers JM, Kenesmans P, Helmerhorst TJ. High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. Br J Obstet Gynecol 2000; 107:600-4.
35. Pater A, Bayatpour M, Pater MA. Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives. Am J Obstet Gynecol 1990;162:1099-103.
36. Chan WK, Klock G, Bernard HU. Progesterone and glucocorticoid response elements occur in the long control region of human papilloma virus-16. J Virol 1989;63:3261-9.
37. Thomas DB, Ray RM. Oral contraceptives and invasive adenocar-cinomas and adenosquamous carcinomas of the uterine cervix. The World Health Organization Collaborative study of neoplasia and steroid contraceptives. Am J Epidemiol 1996;144:281-9.
38. Ylitalo N, Sorensen P, Josefsson AM, et al. Lancet 2000;355: 2194-8.
39. Duggan MA, McGregor SE, Stuart GC, Morris S, Chang-Poon V, Schepansky A, Honore L. The natural history of CIN I lesions. Eur J Gynaecol Oncol 1998;19:338-44.
40. La Vecchia C, Tavani A, Franceschi S, Parazzini F. Oral contraceptives and cancer. A review of the evidence. Drug Saf 1996;14: 260-72.
41. Zondervan KT, Carpenter LM, Painter R, Vessey MP. Oral contraceptives and cervical cancer - further findings from the Oxford Family Planning Association contraceptive study. Multicenter study. Br J Cancer 1996;73:1291-7.